Manali Petro imposes safety mandates on distributors in wake of Coldrif cough syrup crisis

In a direct and stringent response to the health crisis triggered by contaminated Coldrif cough syrup which resulted in the death of at least 21 children, Manali Petrochemicals Limited (MPCL) in Chennai, a key player in India's solvent manufacturing sector, has issued sweeping new mandates for its propylene glycol IP (PG IP) product.

- Peethaambaran, Chennai

The move comes as the Indian pharmaceutical supply chain scrambles to restore confidence following the tragic incidents linked to diethylene glycol (DEG) contamination, a toxic substance that may be mistakenly substituted for or contaminate pharmaceutical-grade solvents.

As one of the three major domestic manufacturers of essential chemical intermediates, MPCL's guidelines are focused on ensuring the integrity of the crucial PG IP, a solvent widely used in pharmaceutical preparations like oral liquids. The company's official instruction sheet explicitly addresses distributors, dealers, and customers, indicating a zero-tolerance approach to quality control from factory gate to final use in manufacturing units. The core message is clear, every stage of the supply chain now requires forensic accountability.